# Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

## TL;DR

This study compares how ceftazidime–avibactam behaves in simulated dialysis and real-life cases in critically ill children.

## Contribution

The study introduces a comparative in vitro/in vivo analysis of ceftazidime–avibactam under high-volume dialysis in children.

## Key findings

- Ceftazidime and avibactam are significantly removed during high-volume CVVHDF.
- Higher dosing or continuous infusion is needed for effective treatment in critically ill children on CRRT.

## Abstract

Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments with continuous venovenous hemodiafiltration (CVVHDF) simulation and a comparison with a previously published in vivo case report. The results highlight the importance of therapeutic drug monitoring and the need for higher dosing or continuous infusion of ceftazidime–avibactam in critically ill children under crontinuous renal replacement therapy (CRRT).